Various authors have recommended caution when prescribing ACE inhibitors or angiotensin-receptor blockers (ARBs) in COVID-19 patients with cardiovascular comorbidity, as this medication can increase ACE2 levels, which could potentially lead to a more severe health outcomes [28,29]. Here, ACE2 is linked to COVID-19.